Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice
Marcela P Cataldi1, Peijuan Lu1, Anthony Blaeser1
1McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Carolinas Healthcare System, Charlotte, NC, 28203, USA.
Abstract:
O-mannosylated α-dystroglycan (α-DG) serves as receptors for cell-cell and cell-extracellular matrix adhesion and signaling. Hypoglycosylation of α-DG is involved in cancer progression and underlies dystroglycanopathy with aberrant neuronal development. Here we report that ribitol, a pentose alcohol with previously unknown function in mammalian cells, partially restores functional O-mannosylation of α-DG (F-α-DG) in the dystroglycanopathy model containing a P448L mutation in fukutin-related protein (FKRP) gene, which is clinically associated with severe congenital muscular dystrophy. Oral administration of ribitol increases levels of ribitol-5-phosphate and CDP-ribitol and restores therapeutic levels of F-α-DG in skeletal and cardiac muscles. Furthermore, ribitol, given before and after the onset of disease phenotype, reduces skeletal muscle pathology, significantly decreases cardiac fibrosis and improves skeletal and respiratory functions in the FKRP mutant mice. Ribitol treatment presents a new class, low risk, and easy to administer experimental therapy to restore F-α-DG in FKRP-related muscular dystrophy.
Insights
Ribitol, a sugar alcohol, partially restores functional O-mannosylation of alpha-dystroglycan (α-DG) in a muscular dystrophy model. This experimental therapy improves muscle pathology and function in FKRP mutant mice.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- O-mannosylated α-dystroglycan (α-DG) is crucial for cell adhesion and signaling.
- Defects in α-DG glycosylation are linked to cancer progression and muscular dystrophies.
Purpose of the Study:
- To investigate the therapeutic potential of ribitol in restoring functional α-DG (F-α-DG) glycosylation.
- To evaluate ribitol's efficacy in a mouse model of FKRP-related congenital muscular dystrophy.
Main Methods:
- Utilized a mouse model with a P448L mutation in the FKRP gene.
- Administered ribitol orally to assess its impact on ribitol-5-phosphate and CDP-ribitol levels.
- Evaluated F-α-DG levels in skeletal and cardiac muscles.
- Assessed muscle pathology, cardiac fibrosis, and functional improvements.
Main Results:
- Ribitol administration restored therapeutic levels of F-α-DG in skeletal and cardiac muscles.
- Treatment reduced skeletal muscle pathology and cardiac fibrosis.
- Ribitol improved skeletal and respiratory functions in FKRP mutant mice.
Conclusions:
- Ribitol shows promise as a novel therapeutic agent for FKRP-related muscular dystrophy.
- Oral ribitol administration is a low-risk, easily administered therapy.
- Restoring F-α-DG levels via ribitol offers a new treatment strategy for dystroglycanopathies.
Related Concept Videos
Functions of Smooth Muscles
Function of visceral smooth muscles
Visceral smooth muscle is found in the walls of all hollow organs, except the heart, and is a key player in the involuntary movements that drive the functioning of these internal organs. This tissue is arranged in...
Mechanical Protein Functions
Functional Groups
Functional Groups
Protein Glycosylation
Glycosylation occurs in...
Functionalism
James envisioned psychology's...


